Novartis

New fault lines emerge in CAR-T therapy
EP Vantage
Tue, 08/24/21 - 10:43 am
CAR-T
Novartis
Kymriah
Bristol Myers Squibb
Beyanzi
Gilead Sciences
Yescarta
clinical trials
Novartis says trials back Beovu safety in diabetic eye disease
Pharmaforum
Tue, 08/17/21 - 10:08 am
Novartis
Beovu
diabetic macular edema
Bayer
Regeneron
Eylea
WHO to study 3 drugs to treat COVID-19
Beckers Hospital Review
Thu, 08/12/21 - 11:08 am
WHO
clinical trials
artesunate
Ipca
JNJ
infliximab
Novartis
imatinib
COVID-19
Novartis looks to manufacturing investment to drive down cost of siRNA drug
Biopharma Reporter
Mon, 08/9/21 - 11:01 am
Novartis
Leqvio
drug manufacturing
siRNA
inclisiran
Novartis to launch new Zolgensma trial after FDA lifts restriction
Reuters
Tue, 08/3/21 - 11:01 am
Novartis
Zolgensma
clinical trials
SMA
FDA
Drugs facing the most patent expirations this year
Drug Patent Watch
Sun, 08/1/21 - 11:46 pm
patents
Novartis
Sunovion
Allergan
Bayer
Gilead Sciences
Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty
Endpoints
Fri, 07/23/21 - 10:57 am
Novartis
patents
Tafinlar
Plexxikon
Daiichi Sankyo
Roche takes the Tim-3 battle to Novartis
EP Vantage
Thu, 07/22/21 - 10:53 am
Roche
sabatolimab
Novartis
RG7769
bispecific antibodies
Novartis Delivers Strong Second Quarter and 50 Million CureVac Vaccines
BioSpace
Wed, 07/21/21 - 08:39 pm
Novartis
earnings
Novartis eyes New Year verdict from FDA on delayed Leqvio
Pharmaforum
Wed, 07/21/21 - 10:58 am
Novartis
FDA
Leqvio
inclisiran
Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie's launches win on value: report
Fierce Pharma
Thu, 07/15/21 - 12:39 pm
Novartis
AbbVie
GSK
Roche
Eli Lilly
AstraZeneca
FDA
drug launches
drug approvals
A Chinese I/O biotech looking to turn around an old Novartis program gets a new fundraise after launching PhIII study
Endpoints
Thu, 07/15/21 - 10:46 am
China
immuno-oncology Adlai Nortye
Novartis
funding
Novartis leads and Bristol lags on novel drug approvals
EP Vantage
Wed, 07/14/21 - 10:10 am
Novartis
Bristol Myers Squibb
drug approvals
FDA
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
Mon, 07/12/21 - 11:08 am
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Motley Fool
Sun, 07/11/21 - 11:13 pm
clinical trials
Novartis
Biogen
SAGE Therapeutics
uniQure
Pfizer
Roche
Big pharma leads the way in stock market resurgence
EP Vantage
Wed, 07/7/21 - 10:49 am
Big Pharma
pharma stocks
Acadia Pharmaceuticals
AstraZeneca
Biogen
Eli Lilly
GSK
Merck
Moderna Therapeutics
Novartis
Sanofi
Provention Bio
Novartis to make Leqvio for U.S. in Austria to overcome FDA delay
Reuters
Tue, 07/6/21 - 11:04 am
Novartis
Leqvio
inclisiran
drug manufacturing
FDA
Austria
Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey
Fierce Pharma
Wed, 06/30/21 - 12:09 am
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
sickle cell disease
gene therapy
Key third-quarter readouts for big pharma
EP Vantage
Tue, 06/29/21 - 10:59 am
clinical trials
Pfizer
Roche
idanacogene elaparvovec
Alexion
AstraZeneca
Ultomiris
AbbVie
Rinvoq
Novartis
sabatolimab
Novartis says it overpaid Roche's Genentech nearly $210 million in a licensing deal—and it wants its money back
Fierce Pharma
Mon, 06/28/21 - 06:53 pm
Novartis
Genentech
California
Chiron

Pages